Lupi-Fsh 75 Injection contains Urofollitropin 75 IU, a purified follicle-stimulating hormone (FSH) derived from the urine of postmenopausal women. It is indicated for the treatment of infertility in women undergoing controlled ovarian stimulation as part of assisted reproductive technologies such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Urofollitropin acts by stimulating the growth and maturation of ovarian follicles, thereby promoting folliculogenesis and increasing the chances of successful ovulation and conception. The dosage and duration of treatment with Lupi-Fsh 75 Injection should be individualized based on patient response, monitored through serum estradiol levels and ultrasound assessment of follicular development. It is contraindicated in cases of primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, and hypersensitivity to gonadotropins. Common adverse effects may include ovarian hyperstimulation syndrome (OHSS), injection site reactions, headache, and abdominal discomfort. Careful monitoring is essential to minimize risks associated with ovarian stimulation. Lupi-Fsh 75 Injection should be administered under the supervision of a healthcare professional experienced in fertility treatments to optimize outcomes and ensure patient safety.

Dosage & How to Use